deltatrials
Unknown PHASE1 NCT00004086

Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer

A Phase I Trial of a Combined Regimen of Chemotherapy and 90Y-Labeled, Humanized LL2 (Anti-CD22) Antibody With Peripheral Stem Cell Rescue for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Sponsor: Garden State Cancer Center at the Center for Molecular Medicine and Immunology

Conditions Leukemia Lymphoma
Interventions autologous bone marrow transplantation cisplatin cytarabine etoposide filgrastim ifosfamide indium In 111 LL2 IgG peripheral blood stem cell transplantation yttrium Y 90 epratuzumab
Updated 5 times since 2017 Last updated: Jun 6, 2009 Started: Jun 30, 1997

This PHASE1 trial investigates Leukemia and Lymphoma and is currently ongoing. Garden State Cancer Center at the Center for Molecular Medicine and Immunology leads this study, which shows 5 recorded versions since 1997 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE1

    First recorded

Jun 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Belleville, United States